nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolcapone—COMT—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0269	0.118	CbGpPWpGaD
Tolcapone—COMT—Dopamine metabolism—NQO1—urinary bladder cancer	0.0135	0.0592	CbGpPWpGaD
Tolcapone—CYP2C9—urine—urinary bladder cancer	0.0123	0.209	CbGeAlD
Tolcapone—COMT—Estrogen metabolism—NQO1—urinary bladder cancer	0.0104	0.0456	CbGpPWpGaD
Tolcapone—Tolmetin—CXCL8—urinary bladder cancer	0.00916	0.483	CrCbGaD
Tolcapone—COMT—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00871	0.0383	CbGpPWpGaD
Tolcapone—COMT—prostate gland—urinary bladder cancer	0.00842	0.143	CbGeAlD
Tolcapone—COMT—Phase II conjugation—GSTO2—urinary bladder cancer	0.00825	0.0363	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—NAT1—urinary bladder cancer	0.00825	0.0363	CbGpPWpGaD
Tolcapone—COMT—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00795	0.035	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00755	0.0332	CbGpPWpGaD
Tolcapone—Tolmetin—MPO—urinary bladder cancer	0.00713	0.376	CrCbGaD
Tolcapone—COMT—seminal vesicle—urinary bladder cancer	0.00712	0.121	CbGeAlD
Tolcapone—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0061	0.0268	CbGpPWpGaD
Tolcapone—COMT—smooth muscle tissue—urinary bladder cancer	0.00596	0.101	CbGeAlD
Tolcapone—COMT—renal system—urinary bladder cancer	0.00574	0.0972	CbGeAlD
Tolcapone—COMT—urethra—urinary bladder cancer	0.00563	0.0954	CbGeAlD
Tolcapone—COMT—Biological oxidations—GSTZ1—urinary bladder cancer	0.00509	0.0224	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00502	0.0221	CbGpPWpGaD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00495	0.0218	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—GSTO2—urinary bladder cancer	0.00483	0.0212	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—NAT1—urinary bladder cancer	0.00483	0.0212	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00476	0.021	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00473	0.0208	CbGpPWpGaD
Tolcapone—COMT—female reproductive system—urinary bladder cancer	0.00459	0.0778	CbGeAlD
Tolcapone—COMT—Phase II conjugation—NAT2—urinary bladder cancer	0.00452	0.0199	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—UGT2B7—urinary bladder cancer	0.00442	0.0194	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00436	0.0192	CbGpPWpGaD
Tolcapone—COMT—vagina—urinary bladder cancer	0.00415	0.0704	CbGeAlD
Tolcapone—COMT—Biological oxidations—CYP4B1—urinary bladder cancer	0.00398	0.0175	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00392	0.0173	CbGpPWpGaD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00373	0.0164	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—HPGDS—urinary bladder cancer	0.00361	0.0159	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—GSTT1—urinary bladder cancer	0.00351	0.0154	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00274	0.0121	CbGpPWpGaD
Tolcapone—COMT—lymph node—urinary bladder cancer	0.00269	0.0455	CbGeAlD
Tolcapone—Tolmetin—PTGS2—urinary bladder cancer	0.00267	0.141	CrCbGaD
Tolcapone—COMT—Biological oxidations—NAT2—urinary bladder cancer	0.00265	0.0116	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00261	0.0115	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—GSTP1—urinary bladder cancer	0.00243	0.0107	CbGpPWpGaD
Tolcapone—CYP2C9—female reproductive system—urinary bladder cancer	0.00242	0.0409	CbGeAlD
Tolcapone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00237	0.0104	CbGpPWpGaD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00234	0.0103	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—GSTM1—urinary bladder cancer	0.00223	0.00983	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—HPGDS—urinary bladder cancer	0.00211	0.00931	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—GSTT1—urinary bladder cancer	0.00205	0.00903	CbGpPWpGaD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00192	0.00846	CbGpPWpGaD
Tolcapone—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00191	0.00842	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00146	0.00642	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—GSTP1—urinary bladder cancer	0.00142	0.00626	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.0014	0.00617	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.00131	0.00575	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—GSTM1—urinary bladder cancer	0.00131	0.00575	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00129	0.00567	CbGpPWpGaD
Tolcapone—COMT—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00129	0.00567	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.00124	0.00545	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.00124	0.00545	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00122	0.00538	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00113	0.00499	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00112	0.00492	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.00102	0.00449	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00101	0.00443	CbGpPWpGaD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000879	0.00387	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GSTZ1—urinary bladder cancer	0.000871	0.00383	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000863	0.0038	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GSTO2—urinary bladder cancer	0.000826	0.00363	CbGpPWpGaD
Tolcapone—COMT—Metabolism—NAT1—urinary bladder cancer	0.000826	0.00363	CbGpPWpGaD
Tolcapone—COMT—Metabolism—UGT2B7—urinary bladder cancer	0.000755	0.00332	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CYP4B1—urinary bladder cancer	0.00068	0.00299	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000679	0.00299	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00067	0.00295	CbGpPWpGaD
Tolcapone—COMT—Metabolism—SLC19A1—urinary bladder cancer	0.000642	0.00283	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PRSS3—urinary bladder cancer	0.000626	0.00275	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000543	0.00239	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000527	0.00232	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000508	0.00224	CbGpPWpGaD
Tolcapone—COMT—Metabolism—TYMP—urinary bladder cancer	0.0005	0.0022	CbGpPWpGaD
Tolcapone—COMT—Metabolism—NAT2—urinary bladder cancer	0.000452	0.00199	CbGpPWpGaD
Tolcapone—Sinusitis—Epirubicin—urinary bladder cancer	0.000437	0.000629	CcSEcCtD
Tolcapone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000437	0.000629	CcSEcCtD
Tolcapone—Pneumonia—Doxorubicin—urinary bladder cancer	0.000434	0.000624	CcSEcCtD
Tolcapone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000434	0.000624	CcSEcCtD
Tolcapone—Pruritus—Fluorouracil—urinary bladder cancer	0.000432	0.000622	CcSEcCtD
Tolcapone—Infestation—Doxorubicin—urinary bladder cancer	0.000431	0.000621	CcSEcCtD
Tolcapone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000431	0.000621	CcSEcCtD
Tolcapone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000426	0.000614	CcSEcCtD
Tolcapone—Bradycardia—Epirubicin—urinary bladder cancer	0.000426	0.000613	CcSEcCtD
Tolcapone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000425	0.000612	CcSEcCtD
Tolcapone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000423	0.000608	CcSEcCtD
Tolcapone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000423	0.000608	CcSEcCtD
Tolcapone—Urticaria—Etoposide—urinary bladder cancer	0.000421	0.000606	CcSEcCtD
Tolcapone—Haemoglobin—Epirubicin—urinary bladder cancer	0.00042	0.000605	CcSEcCtD
Tolcapone—Stomatitis—Doxorubicin—urinary bladder cancer	0.00042	0.000605	CcSEcCtD
Tolcapone—Rhinitis—Epirubicin—urinary bladder cancer	0.000419	0.000604	CcSEcCtD
Tolcapone—Body temperature increased—Etoposide—urinary bladder cancer	0.000419	0.000603	CcSEcCtD
Tolcapone—Abdominal pain—Etoposide—urinary bladder cancer	0.000419	0.000603	CcSEcCtD
Tolcapone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000419	0.000603	CcSEcCtD
Tolcapone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000418	0.000602	CcSEcCtD
Tolcapone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000418	0.000601	CcSEcCtD
Tolcapone—Tinnitus—Methotrexate—urinary bladder cancer	0.000417	0.0006	CcSEcCtD
Tolcapone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000416	0.000599	CcSEcCtD
Tolcapone—Asthenia—Cisplatin—urinary bladder cancer	0.000415	0.000598	CcSEcCtD
Tolcapone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000415	0.000598	CcSEcCtD
Tolcapone—Sweating—Doxorubicin—urinary bladder cancer	0.000413	0.000595	CcSEcCtD
Tolcapone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000413	0.000595	CcSEcCtD
Tolcapone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000412	0.000593	CcSEcCtD
Tolcapone—Haematuria—Doxorubicin—urinary bladder cancer	0.000411	0.000592	CcSEcCtD
Tolcapone—Urethral disorder—Epirubicin—urinary bladder cancer	0.00041	0.00059	CcSEcCtD
Tolcapone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000407	0.000585	CcSEcCtD
Tolcapone—Angiopathy—Methotrexate—urinary bladder cancer	0.000406	0.000584	CcSEcCtD
Tolcapone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000405	0.000582	CcSEcCtD
Tolcapone—Dizziness—Fluorouracil—urinary bladder cancer	0.000404	0.000581	CcSEcCtD
Tolcapone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000403	0.00058	CcSEcCtD
Tolcapone—Chills—Methotrexate—urinary bladder cancer	0.000401	0.000577	CcSEcCtD
Tolcapone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000396	0.00057	CcSEcCtD
Tolcapone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000396	0.000569	CcSEcCtD
Tolcapone—Alopecia—Methotrexate—urinary bladder cancer	0.000395	0.000569	CcSEcCtD
Tolcapone—Vomiting—Gemcitabine—urinary bladder cancer	0.000395	0.000568	CcSEcCtD
Tolcapone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000394	0.000567	CcSEcCtD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000392	0.00172	CbGpPWpGaD
Tolcapone—Mental disorder—Methotrexate—urinary bladder cancer	0.000392	0.000564	CcSEcCtD
Tolcapone—Rash—Gemcitabine—urinary bladder cancer	0.000391	0.000564	CcSEcCtD
Tolcapone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000391	0.000563	CcSEcCtD
Tolcapone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000391	0.000562	CcSEcCtD
Tolcapone—COMT—Metabolism—RRM2—urinary bladder cancer	0.000391	0.00172	CbGpPWpGaD
Tolcapone—Tinnitus—Epirubicin—urinary bladder cancer	0.00039	0.000561	CcSEcCtD
Tolcapone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000389	0.00056	CcSEcCtD
Tolcapone—Headache—Gemcitabine—urinary bladder cancer	0.000389	0.00056	CcSEcCtD
Tolcapone—Vomiting—Fluorouracil—urinary bladder cancer	0.000388	0.000559	CcSEcCtD
Tolcapone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000388	0.000559	CcSEcCtD
Tolcapone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000387	0.000557	CcSEcCtD
Tolcapone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000385	0.000554	CcSEcCtD
Tolcapone—Rash—Fluorouracil—urinary bladder cancer	0.000385	0.000554	CcSEcCtD
Tolcapone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000385	0.000554	CcSEcCtD
Tolcapone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000384	0.000553	CcSEcCtD
Tolcapone—Headache—Fluorouracil—urinary bladder cancer	0.000382	0.000551	CcSEcCtD
Tolcapone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000382	0.00055	CcSEcCtD
Tolcapone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000381	0.000549	CcSEcCtD
Tolcapone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000381	0.000549	CcSEcCtD
Tolcapone—Asthenia—Etoposide—urinary bladder cancer	0.00038	0.000548	CcSEcCtD
Tolcapone—Angiopathy—Epirubicin—urinary bladder cancer	0.00038	0.000546	CcSEcCtD
Tolcapone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000379	0.000546	CcSEcCtD
Tolcapone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000377	0.000543	CcSEcCtD
Tolcapone—Chills—Epirubicin—urinary bladder cancer	0.000375	0.00054	CcSEcCtD
Tolcapone—Pruritus—Etoposide—urinary bladder cancer	0.000375	0.00054	CcSEcCtD
Tolcapone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000374	0.000538	CcSEcCtD
Tolcapone—COMT—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000372	0.00164	CbGpPWpGaD
Tolcapone—Alopecia—Epirubicin—urinary bladder cancer	0.00037	0.000532	CcSEcCtD
Tolcapone—Nausea—Gemcitabine—urinary bladder cancer	0.000369	0.000531	CcSEcCtD
Tolcapone—Vomiting—Cisplatin—urinary bladder cancer	0.000368	0.00053	CcSEcCtD
Tolcapone—Vision blurred—Methotrexate—urinary bladder cancer	0.000367	0.000528	CcSEcCtD
Tolcapone—Mental disorder—Epirubicin—urinary bladder cancer	0.000366	0.000528	CcSEcCtD
Tolcapone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000366	0.000527	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000365	0.00161	CbGpPWpGaD
Tolcapone—Rash—Cisplatin—urinary bladder cancer	0.000365	0.000525	CcSEcCtD
Tolcapone—Dermatitis—Cisplatin—urinary bladder cancer	0.000365	0.000525	CcSEcCtD
Tolcapone—Diarrhoea—Etoposide—urinary bladder cancer	0.000363	0.000522	CcSEcCtD
Tolcapone—Nausea—Fluorouracil—urinary bladder cancer	0.000363	0.000522	CcSEcCtD
Tolcapone—COMT—Metabolism—HPGDS—urinary bladder cancer	0.000362	0.00159	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ENO2—urinary bladder cancer	0.000362	0.00159	CbGpPWpGaD
Tolcapone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000361	0.00052	CcSEcCtD
Tolcapone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000361	0.000519	CcSEcCtD
Tolcapone—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00036	0.00158	CbGpPWpGaD
Tolcapone—Anaemia—Methotrexate—urinary bladder cancer	0.00036	0.000518	CcSEcCtD
Tolcapone—Flatulence—Epirubicin—urinary bladder cancer	0.000359	0.000517	CcSEcCtD
Tolcapone—Tension—Epirubicin—urinary bladder cancer	0.000357	0.000514	CcSEcCtD
Tolcapone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000357	0.000513	CcSEcCtD
Tolcapone—Nervousness—Epirubicin—urinary bladder cancer	0.000354	0.000509	CcSEcCtD
Tolcapone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000351	0.000506	CcSEcCtD
Tolcapone—Malaise—Methotrexate—urinary bladder cancer	0.000351	0.000505	CcSEcCtD
Tolcapone—COMT—Metabolism—GSTT1—urinary bladder cancer	0.000351	0.00154	CbGpPWpGaD
Tolcapone—Dizziness—Etoposide—urinary bladder cancer	0.000351	0.000505	CcSEcCtD
Tolcapone—Muscle spasms—Epirubicin—urinary bladder cancer	0.00035	0.000504	CcSEcCtD
Tolcapone—Vertigo—Methotrexate—urinary bladder cancer	0.00035	0.000503	CcSEcCtD
Tolcapone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000349	0.000502	CcSEcCtD
Tolcapone—Chills—Doxorubicin—urinary bladder cancer	0.000347	0.0005	CcSEcCtD
Tolcapone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000346	0.000498	CcSEcCtD
Tolcapone—Nausea—Cisplatin—urinary bladder cancer	0.000344	0.000495	CcSEcCtD
Tolcapone—Vision blurred—Epirubicin—urinary bladder cancer	0.000343	0.000494	CcSEcCtD
Tolcapone—Alopecia—Doxorubicin—urinary bladder cancer	0.000342	0.000492	CcSEcCtD
Tolcapone—Cough—Methotrexate—urinary bladder cancer	0.00034	0.000489	CcSEcCtD
Tolcapone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000339	0.000488	CcSEcCtD
Tolcapone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000338	0.000486	CcSEcCtD
Tolcapone—Vomiting—Etoposide—urinary bladder cancer	0.000337	0.000485	CcSEcCtD
Tolcapone—Anaemia—Epirubicin—urinary bladder cancer	0.000337	0.000484	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000335	0.00148	CbGpPWpGaD
Tolcapone—Agitation—Epirubicin—urinary bladder cancer	0.000335	0.000482	CcSEcCtD
Tolcapone—Rash—Etoposide—urinary bladder cancer	0.000334	0.000481	CcSEcCtD
Tolcapone—Dermatitis—Etoposide—urinary bladder cancer	0.000334	0.000481	CcSEcCtD
Tolcapone—Headache—Etoposide—urinary bladder cancer	0.000332	0.000478	CcSEcCtD
Tolcapone—Flatulence—Doxorubicin—urinary bladder cancer	0.000332	0.000478	CcSEcCtD
Tolcapone—Myalgia—Methotrexate—urinary bladder cancer	0.000331	0.000477	CcSEcCtD
Tolcapone—Arthralgia—Methotrexate—urinary bladder cancer	0.000331	0.000477	CcSEcCtD
Tolcapone—Chest pain—Methotrexate—urinary bladder cancer	0.000331	0.000477	CcSEcCtD
Tolcapone—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000331	0.00146	CbGpPWpGaD
Tolcapone—Tension—Doxorubicin—urinary bladder cancer	0.000331	0.000476	CcSEcCtD
Tolcapone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00033	0.000475	CcSEcCtD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000329	0.000474	CcSEcCtD
Tolcapone—Malaise—Epirubicin—urinary bladder cancer	0.000328	0.000473	CcSEcCtD
Tolcapone—Discomfort—Methotrexate—urinary bladder cancer	0.000327	0.000471	CcSEcCtD
Tolcapone—Nervousness—Doxorubicin—urinary bladder cancer	0.000327	0.000471	CcSEcCtD
Tolcapone—Vertigo—Epirubicin—urinary bladder cancer	0.000327	0.000471	CcSEcCtD
Tolcapone—Syncope—Epirubicin—urinary bladder cancer	0.000327	0.00047	CcSEcCtD
Tolcapone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000324	0.000466	CcSEcCtD
Tolcapone—Palpitations—Epirubicin—urinary bladder cancer	0.000322	0.000463	CcSEcCtD
Tolcapone—Confusional state—Methotrexate—urinary bladder cancer	0.00032	0.000461	CcSEcCtD
Tolcapone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00032	0.000461	CcSEcCtD
Tolcapone—Cough—Epirubicin—urinary bladder cancer	0.000318	0.000457	CcSEcCtD
Tolcapone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000318	0.000457	CcSEcCtD
Tolcapone—Infection—Methotrexate—urinary bladder cancer	0.000316	0.000454	CcSEcCtD
Tolcapone—Nausea—Etoposide—urinary bladder cancer	0.000315	0.000453	CcSEcCtD
Tolcapone—Hypertension—Epirubicin—urinary bladder cancer	0.000314	0.000453	CcSEcCtD
Tolcapone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000313	0.00045	CcSEcCtD
Tolcapone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000311	0.000448	CcSEcCtD
Tolcapone—Anaemia—Doxorubicin—urinary bladder cancer	0.000311	0.000448	CcSEcCtD
Tolcapone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000311	0.000448	CcSEcCtD
Tolcapone—Myalgia—Epirubicin—urinary bladder cancer	0.00031	0.000446	CcSEcCtD
Tolcapone—Arthralgia—Epirubicin—urinary bladder cancer	0.00031	0.000446	CcSEcCtD
Tolcapone—Chest pain—Epirubicin—urinary bladder cancer	0.00031	0.000446	CcSEcCtD
Tolcapone—Agitation—Doxorubicin—urinary bladder cancer	0.00031	0.000446	CcSEcCtD
Tolcapone—Anxiety—Epirubicin—urinary bladder cancer	0.000309	0.000445	CcSEcCtD
Tolcapone—Skin disorder—Methotrexate—urinary bladder cancer	0.000308	0.000444	CcSEcCtD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000308	0.000443	CcSEcCtD
Tolcapone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000307	0.000442	CcSEcCtD
Tolcapone—Discomfort—Epirubicin—urinary bladder cancer	0.000306	0.000441	CcSEcCtD
Tolcapone—Malaise—Doxorubicin—urinary bladder cancer	0.000304	0.000437	CcSEcCtD
Tolcapone—Dry mouth—Epirubicin—urinary bladder cancer	0.000303	0.000436	CcSEcCtD
Tolcapone—Vertigo—Doxorubicin—urinary bladder cancer	0.000303	0.000436	CcSEcCtD
Tolcapone—Anorexia—Methotrexate—urinary bladder cancer	0.000303	0.000436	CcSEcCtD
Tolcapone—Syncope—Doxorubicin—urinary bladder cancer	0.000302	0.000435	CcSEcCtD
Tolcapone—Confusional state—Epirubicin—urinary bladder cancer	0.0003	0.000431	CcSEcCtD
Tolcapone—Palpitations—Doxorubicin—urinary bladder cancer	0.000298	0.000429	CcSEcCtD
Tolcapone—Oedema—Epirubicin—urinary bladder cancer	0.000297	0.000428	CcSEcCtD
Tolcapone—Hypotension—Methotrexate—urinary bladder cancer	0.000297	0.000427	CcSEcCtD
Tolcapone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000296	0.000426	CcSEcCtD
Tolcapone—Infection—Epirubicin—urinary bladder cancer	0.000295	0.000425	CcSEcCtD
Tolcapone—Cough—Doxorubicin—urinary bladder cancer	0.000294	0.000423	CcSEcCtD
Tolcapone—Shock—Epirubicin—urinary bladder cancer	0.000292	0.000421	CcSEcCtD
Tolcapone—COMT—Metabolism—NQO1—urinary bladder cancer	0.000292	0.00128	CbGpPWpGaD
Tolcapone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000291	0.00042	CcSEcCtD
Tolcapone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000291	0.000419	CcSEcCtD
Tolcapone—Hypertension—Doxorubicin—urinary bladder cancer	0.000291	0.000419	CcSEcCtD
Tolcapone—Tachycardia—Epirubicin—urinary bladder cancer	0.00029	0.000418	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000289	0.000416	CcSEcCtD
Tolcapone—Skin disorder—Epirubicin—urinary bladder cancer	0.000289	0.000416	CcSEcCtD
Tolcapone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000287	0.000414	CcSEcCtD
Tolcapone—Myalgia—Doxorubicin—urinary bladder cancer	0.000287	0.000413	CcSEcCtD
Tolcapone—Chest pain—Doxorubicin—urinary bladder cancer	0.000287	0.000413	CcSEcCtD
Tolcapone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000287	0.000413	CcSEcCtD
Tolcapone—Anxiety—Doxorubicin—urinary bladder cancer	0.000286	0.000411	CcSEcCtD
Tolcapone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000285	0.00041	CcSEcCtD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000285	0.00041	CcSEcCtD
Tolcapone—COMT—Neuronal System—HRAS—urinary bladder cancer	0.000285	0.00125	CbGpPWpGaD
Tolcapone—Discomfort—Doxorubicin—urinary bladder cancer	0.000283	0.000408	CcSEcCtD
Tolcapone—Anorexia—Epirubicin—urinary bladder cancer	0.000283	0.000408	CcSEcCtD
Tolcapone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000283	0.000408	CcSEcCtD
Tolcapone—Somnolence—Methotrexate—urinary bladder cancer	0.000282	0.000406	CcSEcCtD
Tolcapone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000281	0.000404	CcSEcCtD
Tolcapone—Dyspepsia—Methotrexate—urinary bladder cancer	0.00028	0.000402	CcSEcCtD
Tolcapone—Hypotension—Epirubicin—urinary bladder cancer	0.000278	0.0004	CcSEcCtD
Tolcapone—Confusional state—Doxorubicin—urinary bladder cancer	0.000277	0.000399	CcSEcCtD
Tolcapone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000276	0.000397	CcSEcCtD
Tolcapone—Oedema—Doxorubicin—urinary bladder cancer	0.000275	0.000396	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000274	0.000395	CcSEcCtD
Tolcapone—Fatigue—Methotrexate—urinary bladder cancer	0.000274	0.000394	CcSEcCtD
Tolcapone—Infection—Doxorubicin—urinary bladder cancer	0.000273	0.000393	CcSEcCtD
Tolcapone—Pain—Methotrexate—urinary bladder cancer	0.000272	0.000391	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000271	0.00039	CcSEcCtD
Tolcapone—Shock—Doxorubicin—urinary bladder cancer	0.000271	0.000389	CcSEcCtD
Tolcapone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00027	0.000388	CcSEcCtD
Tolcapone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000269	0.000388	CcSEcCtD
Tolcapone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000268	0.000386	CcSEcCtD
Tolcapone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000267	0.000384	CcSEcCtD
Tolcapone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000267	0.000384	CcSEcCtD
Tolcapone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000266	0.000383	CcSEcCtD
Tolcapone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000265	0.000381	CcSEcCtD
Tolcapone—Somnolence—Epirubicin—urinary bladder cancer	0.000264	0.00038	CcSEcCtD
Tolcapone—Anorexia—Doxorubicin—urinary bladder cancer	0.000262	0.000377	CcSEcCtD
Tolcapone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000262	0.000377	CcSEcCtD
Tolcapone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000262	0.000377	CcSEcCtD
Tolcapone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00026	0.000374	CcSEcCtD
Tolcapone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000258	0.000372	CcSEcCtD
Tolcapone—Hypotension—Doxorubicin—urinary bladder cancer	0.000257	0.00037	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000257	0.000369	CcSEcCtD
Tolcapone—Fatigue—Epirubicin—urinary bladder cancer	0.000256	0.000369	CcSEcCtD
Tolcapone—Pain—Epirubicin—urinary bladder cancer	0.000254	0.000366	CcSEcCtD
Tolcapone—Constipation—Epirubicin—urinary bladder cancer	0.000254	0.000366	CcSEcCtD
Tolcapone—Urticaria—Methotrexate—urinary bladder cancer	0.000252	0.000363	CcSEcCtD
Tolcapone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000251	0.000361	CcSEcCtD
Tolcapone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000251	0.000361	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000251	0.000361	CcSEcCtD
Tolcapone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000247	0.000355	CcSEcCtD
Tolcapone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000245	0.000353	CcSEcCtD
Tolcapone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000245	0.000353	CcSEcCtD
Tolcapone—Somnolence—Doxorubicin—urinary bladder cancer	0.000244	0.000352	CcSEcCtD
Tolcapone—COMT—Metabolism—GSTP1—urinary bladder cancer	0.000243	0.00107	CbGpPWpGaD
Tolcapone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000243	0.00035	CcSEcCtD
Tolcapone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000242	0.000348	CcSEcCtD
Tolcapone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000239	0.000344	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000237	0.000342	CcSEcCtD
Tolcapone—Fatigue—Doxorubicin—urinary bladder cancer	0.000237	0.000341	CcSEcCtD
Tolcapone—Urticaria—Epirubicin—urinary bladder cancer	0.000236	0.00034	CcSEcCtD
Tolcapone—Pain—Doxorubicin—urinary bladder cancer	0.000235	0.000339	CcSEcCtD
Tolcapone—Constipation—Doxorubicin—urinary bladder cancer	0.000235	0.000339	CcSEcCtD
Tolcapone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000235	0.000338	CcSEcCtD
Tolcapone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000235	0.000338	CcSEcCtD
Tolcapone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000234	0.000337	CcSEcCtD
Tolcapone—Asthenia—Methotrexate—urinary bladder cancer	0.000228	0.000328	CcSEcCtD
Tolcapone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000227	0.000326	CcSEcCtD
Tolcapone—COMT—Metabolism—TYMS—urinary bladder cancer	0.000226	0.000995	CbGpPWpGaD
Tolcapone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000225	0.000324	CcSEcCtD
Tolcapone—Pruritus—Methotrexate—urinary bladder cancer	0.000225	0.000323	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000224	0.000984	CbGpPWpGaD
Tolcapone—COMT—Metabolism—NCOR1—urinary bladder cancer	0.000223	0.000983	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GSTM1—urinary bladder cancer	0.000223	0.000983	CbGpPWpGaD
Tolcapone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000219	0.000315	CcSEcCtD
Tolcapone—Urticaria—Doxorubicin—urinary bladder cancer	0.000218	0.000314	CcSEcCtD
Tolcapone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000217	0.000313	CcSEcCtD
Tolcapone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000217	0.000313	CcSEcCtD
Tolcapone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000217	0.000313	CcSEcCtD
Tolcapone—COMT—Metabolism—GPX1—urinary bladder cancer	0.000214	0.000941	CbGpPWpGaD
Tolcapone—Asthenia—Epirubicin—urinary bladder cancer	0.000213	0.000307	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000212	0.000933	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000212	0.000933	CbGpPWpGaD
Tolcapone—Pruritus—Epirubicin—urinary bladder cancer	0.00021	0.000303	CcSEcCtD
Tolcapone—COMT—Metabolism—ERCC2—urinary bladder cancer	0.00021	0.000924	CbGpPWpGaD
Tolcapone—Dizziness—Methotrexate—urinary bladder cancer	0.00021	0.000302	CcSEcCtD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000208	0.000917	CbGpPWpGaD
Tolcapone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000203	0.000293	CcSEcCtD
Tolcapone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000203	0.000292	CcSEcCtD
Tolcapone—Vomiting—Methotrexate—urinary bladder cancer	0.000202	0.000291	CcSEcCtD
Tolcapone—Rash—Methotrexate—urinary bladder cancer	0.0002	0.000288	CcSEcCtD
Tolcapone—Dermatitis—Methotrexate—urinary bladder cancer	0.0002	0.000288	CcSEcCtD
Tolcapone—Headache—Methotrexate—urinary bladder cancer	0.000199	0.000286	CcSEcCtD
Tolcapone—COMT—Metabolism—MTHFR—urinary bladder cancer	0.000197	0.000869	CbGpPWpGaD
Tolcapone—Asthenia—Doxorubicin—urinary bladder cancer	0.000197	0.000284	CcSEcCtD
Tolcapone—Dizziness—Epirubicin—urinary bladder cancer	0.000197	0.000283	CcSEcCtD
Tolcapone—Pruritus—Doxorubicin—urinary bladder cancer	0.000195	0.00028	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000194	0.000853	CbGpPWpGaD
Tolcapone—Vomiting—Epirubicin—urinary bladder cancer	0.000189	0.000272	CcSEcCtD
Tolcapone—Nausea—Methotrexate—urinary bladder cancer	0.000189	0.000272	CcSEcCtD
Tolcapone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000188	0.000271	CcSEcCtD
Tolcapone—Rash—Epirubicin—urinary bladder cancer	0.000187	0.00027	CcSEcCtD
Tolcapone—Dermatitis—Epirubicin—urinary bladder cancer	0.000187	0.000269	CcSEcCtD
Tolcapone—Headache—Epirubicin—urinary bladder cancer	0.000186	0.000268	CcSEcCtD
Tolcapone—Dizziness—Doxorubicin—urinary bladder cancer	0.000182	0.000262	CcSEcCtD
Tolcapone—Nausea—Epirubicin—urinary bladder cancer	0.000177	0.000254	CcSEcCtD
Tolcapone—Vomiting—Doxorubicin—urinary bladder cancer	0.000175	0.000252	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000175	0.000768	CbGpPWpGaD
Tolcapone—Rash—Doxorubicin—urinary bladder cancer	0.000173	0.00025	CcSEcCtD
Tolcapone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000173	0.000249	CcSEcCtD
Tolcapone—Headache—Doxorubicin—urinary bladder cancer	0.000172	0.000248	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.000165	0.000725	CbGpPWpGaD
Tolcapone—Nausea—Doxorubicin—urinary bladder cancer	0.000163	0.000235	CcSEcCtD
Tolcapone—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	0.000161	0.000707	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PPARG—urinary bladder cancer	0.00016	0.000705	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CREBBP—urinary bladder cancer	0.000154	0.000677	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000129	0.000567	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—TYMP—urinary bladder cancer	0.000128	0.000565	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PTGS2—urinary bladder cancer	0.000126	0.000554	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000123	0.000543	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—NAT2—urinary bladder cancer	0.000116	0.000511	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PTEN—urinary bladder cancer	0.00011	0.000483	CbGpPWpGaD
Tolcapone—COMT—Metabolism—EP300—urinary bladder cancer	0.000105	0.000461	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—RRM2—urinary bladder cancer	0.0001	0.000441	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.29e-05	0.000409	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.29e-05	0.000409	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.23e-05	0.000406	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.01e-05	0.000396	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.87e-05	0.00039	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.48e-05	0.000329	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.26e-05	0.00032	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.33e-05	0.000279	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.24e-05	0.000275	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.04e-05	0.000266	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	5.8e-05	0.000255	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	5.74e-05	0.000252	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	5.74e-05	0.000252	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.49e-05	0.000242	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.39e-05	0.000237	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.07e-05	0.000223	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.11e-05	0.000181	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.95e-05	0.000174	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.23e-05	0.000142	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.82e-05	0.000124	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.69e-05	0.000118	CbGpPWpGaD
